Please login to the form below

Not currently logged in
Email:
Password:

Brexit and the pharmaceutical industry

News & Analysis: how the UK's departure from the EU will impact pharma and the life sciences sector

Industry pleads for compromise after Brexit defeat

Industry pleads for compromise after Brexit defeat

The moment when MPs revealed the scale of the government's Brexit defeat: 432 votes to 202. ... The focus of pharmaceutical companies is on making sure that medicines and vaccines get to patients whatever the Brexit outcome,” added Thompson.

Latest news

  • Crunch time as Brexit deal faces ‘meaningful vote’ Crunch time as Brexit deal faces ‘meaningful vote’

    Rejecting the deal would either result in a no deal or no Brexit, warns May. ... with the EU, warning that rejecting it would mean either no deal or no Brexit, and risk breaking up the UK.

  • Time running out for ‘no-deal’ Brexit medicines laws Time running out for ‘no-deal’ Brexit medicines laws

    which would allow the MHRA to function in the even of a no deal Brexit. ... However public opinion polls show most voters - whether former 'Remain' or 'Leave' voters opposed to Theresa May's Brexit deal.

  • Blackwood returns as new life sciences minister Blackwood returns as new life sciences minister

    Roche, Celgene, IQVIA and Oxford Biomedica. Her role also includes looking at ways in which the sector can make the most of Brexit - although the UK's pharma and biotech sector ... MPs in the House of Commons will finally have their chance to vote on the

  • NHS facing early exodus of skilled consultants NHS facing early exodus of skilled consultants

    Just 7% plan to stay after the age of 65. It’s a sobering thought in light of the staffing uncertainties posed by Brexit – particularly plans for a minimum salary threshold ... The figures come against a backdrop of uncertainty with a possible Brexit

  • EMA sees approval numbers rise in 2018 EMA sees approval numbers rise in 2018

    These were Roche’s Hemlibra, Shire’s Takhzyro, Alnylam’s Onpattro and Tegsedi. US shutdown and Brexit. ... to plan for licensing and regulatory updates, including the impact of a potential no deal Brexit.

More from news
Approximately 111 fully matching, plus 53 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 18 fully matching, plus 24 partially matching documents found.

Latest from PMHub

  • Givers and Takers

    Noisy politicians who think Brexit is purely about what the UK wants as opposed to a win/win for everyone, impatient drivers who think their journey is more important than those

  • Artificial Intelligence in Healthcare

    Presently, the looming Brexit saga is casting shadows over the UK’s ability to play host to clinical trials at the frontiers of medical innovation.

  • What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government

    With a fresh general election less than four years away and the current government struggling to pass its Brexit plans through Parliament, the prospect of Prime Minister Jeremy Corbyn is one

  • Training the next generation of biotech leaders

    of Brexit, and how the next generation is paving the way for innovation. ... universities. With Brexit on the horizon, there is a worry that the already low number of UK scientists with expertise in cell and gene therapy will dwindle further.

  • Synergy Vision

    Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma and agency experience means that we understand our clients and can deliver bespoke medical

More from PMHub
Approximately 5 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics